VERTEX PHARMACEUTICALS INC (VRTX) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 75% based on the firm’s underlying fundamentals and the ...

Vertex Pharmaceuticals VRTX +1.22% Get Free Report has outperformed the market over the past 20 years by 10.58% on an ...

The stock's fall snapped a four-day winning streak.

Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 15 years ago, it would be worth $11,812.35 today based on ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

With a market cap of $114.8 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company specializing in ...

However, sales from its new drugs, Casgevy, Alyftrek and Journavx, fell short of investor expectations, which, coupled with the disappointing first-quarter results, led VRTX stock to decline 10% ...

CRISPR Therapeutics stock is down more than 80% from the peak ... Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose ...

We have seen 790 institutional investors add shares of $VRTX stock to their portfolio, and 790 decrease their positions in their most recent quarter. $VRTX insiders ...

Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, May 5, 2025. For those trading based on events, analyzing historical stock behavior around earnings announcements can ...